Method of providing aripiprazole to patients having impaired cyp2d6 or cyp3a4 enzyme function
AssigneeOtsuka Pharmaceutical Co., Ltd.
InventorArash Raoufinia
Life of this patent
Estimating the term…
Abstract
The disclosed embodiments relate to methods of initiating aripiprazole treatment in a patient who is a CYP2D6 poor metabolizer or a CYP3A4 poor metabolizer, or both.
Claims22
A method of initiating aripiprazole treatment in a patient in need thereof who is (a) a CYP2D6 poor metabolizer not concomitantly administered a strong CYP3A4 or CYP2D6 inhibitor, or (b) an extensive metabolizer concomitantly administered a strong CYP2D6 or CYP3A4 inhibitor, comprising:
- administering intramuscularly to said patient a starting dose of a long-acting drug-containing suspension which provides therapeutic plasma levels of aripiprazole over a period of about one month;
- wherein said starting dose provides about 75% of the amount of aripiprazole compared to an initial dose recommended for a patient with normal CYP2D6 and CYP3A4 enzyme function.
2-3. (canceled)
A method of initiating aripiprazole treatment in a patient in need thereof who is either (a) a CYP2D6 poor metabolizer and is concomitantly administered a strong CYP3A4 inhibitor, or (b) an extensive metabolizer concomitantly administered a strong CYP3A4 and a strong CYP2D6 inhibitor, said method comprising:
- administering intramuscularly to said patient a starting dose of a long-acting drug-containing suspension which provides therapeutic plasma levels of aripiprazole over a period of about one month, wherein said starting dose provides about 50% of the amount of aripiprazole compared to the initial dose recommended for a patient with normal CYP2D6 and CYP3A4 enzyme function.
5-11. (canceled)
(canceled)
17-18. (canceled)
Dependencies are inferred from the claim text.